Raxar (grepafloxacin)

Company
GlaxoSmithKline

Approval Status
Approved November 1997

Treatment for
chronic bronchitis

Areas
Respiratory

Raxar (grepafloxacin) has been approved for mild to moderate cases of acute bacterial exacerbations of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis; for community-acquired pneumonia caused by the same bacteria as well as Mycoplasma pneumoniae; for uncomplicated gonorrhea caused by Neissaria gonorrhoeae; and for nongonococcal urethritis and cervicitis caused by Chlymidia trachomatis.

Raxar tablets are contraindicated in patients with hepatic failure.

Adverse reactions for a multiple-dose regimen of Raxar 600 mg include a 15.8% incidence of nausea, 17.8% of taste perversion, 5.7% of vomiting, 5.4% of dizziness, 4.2% of diarrhea, and 2.2% of constipation.

Raxar (grepafloxacin) Drug Information

The Raxar (grepafloxacin) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top